<DOC>
	<DOCNO>NCT02721888</DOCNO>
	<brief_summary>Non-alcoholic fatty liver disease ( NAFLD ) commonly associate obesity , metabolic syndrome type 2 diabetes . NAFLD , patient type 2 diabetes , show associated lipid abnormality ( hypertriglyceridemia decrease HDL-cholesterol ) increase cardiovascular risk . Such lipid abnormality ( hypertriglyceridemia decrease HDL-cholesterol ) frequent patient type 2 diabetes . Moreover , NAFLD risk development cirrhosis ( estimate 3 5 % ) . Animal study show liraglutide able decrease liver fat content , effect liraglutide liver fat content patient diabetes remains unknown . In addition , human study liraglutide show significant modification plasma lipid , reduction plasma triglyceride LDL-cholesterol . However , mechanism responsible liraglutide induced lipid modification yet know . Because increase liver fat content hypertriglyceridemia associate patient type 2 diabetes , seem interesting study effect liraglutide liver fat content lipid metabolism use gold-standard method ( proton-spectroscopy liver fat content assessment kinetic study stable isotope study lipoprotein metabolism ) . This monocentric study . Fatty liver content perform proton-spectroscopy patient type 2 diabetes ( n=120 ) 6 month period liraglutide therapy ( 1.2 mg/day ) . Moreover , vivo kinetic study perform stable isotope ( 13C leucine ) 10 patient among 120 patient type 2 diabetes ( n=10 ) 6-month period liraglutide ( 1.2 mg/day ) therapy . Each kinetic study perform 2-day hospitalization For main study , 3 visit perform : - first visit T0 , start treatment liraglutide , include clinical biological measurement liver fat content assessment proton-spectroscopy - visit 3 month include clinical biological measurement - visit 6 month include clinical biological measurement liver fat content assessment proton-spectroscopy For kinetic substudy , perform 10 patient , kinetic study stable isotope performs 48h-hospitalization start treatment liraglutide 6 month-treatment liraglutide</brief_summary>
	<brief_title>Effect Liraglutide Fatty Liver Content Lipoprotein Metabolism</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients type 2 diabetes Patients treat metformin and/or sulfonylurea ( glinides ) and/or acarbose and/or insulin , HbA1C &gt; = 7 % , Patients give write consent . For kinetic substudy : Patients typical feature diabetic dyslipidemia ( triglycerides &gt; = 1.50 g/l and/or HDL &lt; 0.50 g/l [ woman ] , 0.40 g/l [ men ] ) Treatment thiazolidinediones Glucagonlike peptide1 ( GLP1 ) agonist . No treatment Dipeptidyl peptidase4 ( DPP4 ) inhibitor 3 previous month , Renal hepatic failure , Contraindication protonspectroscopy ( pacemaker , implantable prosthesis , .. ) , Pregnancy . For kinetic substudy : Patients hypolipidemic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>